Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Cool, topped my own modest stake up a couple of weeks back around 3.2p and optimistic that this will return to the 5p level later in 2019. Buy and hold bio tiddler every portfolio should have one!
Great presentation https://youtu.be/xV3nZD8PN08
Some serious buying going on in the background.
Commenting on outlook, Hilary Spence, CFO says: "We have seen a return to growth in the first six months of the financial year and we remain on track to meet our financial performance objectives in line with market expectations. The management team has continued to generate a large number of business leads, some of which may require incremental upfront investment on initiation.
Whilst there is no current financial year requirement, with one eye on exploiting opportunities for future financial years this variation provides management greater flexibility to deliver on these leads and on other growth opportunities that will contribute to future performance."
That wasn't you that just bought another massive chunk there was it????
All £13.04 worth lol.
Big investment or a crazy code lol.
Yes I bought a chunk this week on the news having previously sold 2/3 at just above 4p.
Speculative buy imo.
Would be nice if share price reflected this but no volume in here yet.Let's hope it gets some notice soon.
Great update. CE mark progressing well with no issues. New contracts and revenues on track. He sounds really positive about the progress and opportunities.
Very good RNS, revenues higher and more contracts being signed. Looking very promising for the second half of the year.
Gonna have to say strange to that statement. Wasn't on RNS released yesterday on on any site i seen,however LSE decide to add on there version of it?
Unless i'm missing something?
"We anticipate that we will have a significant year of growth and change, and it will be a transitional year in terms of new product development and revenue generation," the AIM-listed company said. http://www.lse.co.uk/sharecast-news-article.asp?shareprice=&ArticleCode=28154343&ArticleHeadline=Collagen_Solutions_CEO_to_present_update_at_biotech_showcase_next_month
Down so much on a few grand of sell certainly stinks imo.
Given the 12% drop maybe someone has heard bad news? Could equally be shorting prior to a buy.
Its also time for the october trading statement
they did say they would increase coms and visabilty so time for an update in my opinion. Agree CE update would be good. They said previously that they had done the audit. “ChondroMimetic® is on track for both CE Mark and first-in-man surgery in this financial year, following a successful audit by our notified body regulator” That appears to be part of step 6 of the process. https://www.emergobyul.com/resources/europe-process-chart Step 7 is the granting of CE marking.
Does anyone have any idea when news is expected?
i.e when CE mark for ChondroMimetic product line?
If this can get approved and start selling it then i expect some action with COS. IMO
Any opinions
https://www.hardmanandco.com/companies/collagen-solutions-plc/
https://depositormoney.com/bovine-based-collagen-for-biomedical-applications-market-to-reach-an-opportunity-of-us-1300-mn-by-2025/ Collagen for Biomedical Applications Market to Reach an Opportunity of US$ 1300 Mn by 2025 “The report also provides profiles of leading players operating in the global bovine-based collagen for biomedical applications market. Collagen Solutions LLP and Medtronic are the major players operating in the market, offering products with proprietary technologies.” “ In September 2015, Collagen Solutions acquired all assets and exclusive worldwide license from ChondroMimetic from Orthomimetics Limited and Cambridge Enterprise Ltd. ChondroMimetic is primarily a manufacturer of collagen-based implants utilized for the treatment of small osteochondral defects. This acquisition provided Collagen Solutions with official license to sell regenerative medical products in the orthobiologics market across the globe.”
And another 650k purchase by the Chairman this time Very confident/clear signal for what’s to come in my opinion.
And now another 1.5 million.
All looking very positive, hopefully we get an operational update soon. Medica trade fair event coming up in november. Interims in december, so lots of news updates to come. Then we have the CE marking updates which could be huge by itself. Directors clearly positioning with stock purchases at market prices and future stock options.
FT reports a director Tom Hyland purchased just over 115,000 shares this week.
Encouraging news imo.